HomeCompareMANT vs JNJ

MANT vs JNJ: Dividend Comparison 2026

MANT yields 11.65% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MANT wins by $10591.03M in total portfolio value
10 years
MANT
MANT
● Live price
11.65%
Share price
$95.98
Annual div
$11.18
5Y div CAGR
79.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10591.06M
Annual income
$10,097,255,534.53
Full MANT calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MANT vs JNJ

📍 MANT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMANTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MANT + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MANT pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MANT
Annual income on $10K today (after 15% tax)
$990.10/yr
After 10yr DRIP, annual income (after tax)
$8,582,667,204.35/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, MANT beats the other by $8,582,663,218.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MANT + JNJ for your $10,000?

MANT: 50%JNJ: 50%
100% JNJ50/50100% MANT
Portfolio after 10yr
$5295.55M
Annual income
$5,048,630,111.97/yr
Blended yield
95.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MANT
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MANT buys
0
JNJ buys
0
No recent congressional trades found for MANT or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMANTJNJ
Forward yield11.65%2.13%
Annual dividend / share$11.18$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR79.4%28%
Portfolio after 10y$10591.06M$30.3K
Annual income after 10y$10,097,255,534.53$4,689.40
Total dividends collected$10556.13M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MANT vs JNJ ($10,000, DRIP)

YearMANT PortfolioMANT Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,790$2,089.70$10,592$272.30+$2.2KMANT
2$18,166$4,481.08$11,289$357.73+$6.9KMANT
3$30,109$10,671.40$12,123$472.89+$18.0KMANT
4$61,872$29,654.93$13,141$629.86+$48.7KMANT
5$168,374$102,171.51$14,408$846.81+$154.0KMANT
6$646,339$466,178.54$16,021$1,151.60+$630.3KMANT
7$3,691,959$3,000,376.53$18,122$1,588.22+$3.67MMANT
8$32,685,384$28,734,987.44$20,930$2,228.20+$32.66MMANT
9$461,500,208$426,526,847.68$24,792$3,191.91+$461.48MMANT
10$10,591,060,757$10,097,255,534.53$30,274$4,689.40+$10591.03MMANT

MANT vs JNJ: Complete Analysis 2026

MANTStock

ManTech International Corporation provides technology solutions and services for U.S. defense, intelligence community, and federal civilian agencies worldwide. The company offers cyber solutions and services, including security operations, threat intelligence, incident response and forensics, boundary defense, security systems engineering, infrastructure security, and computer forensics and exploitation. It also provides IT and digital modernization, cloud solutions, managed and integrated services management, IT-as-a services, edge computing, user engagement, and experience and digital workplace transformation; and data collection and management, predictive analytics, analytics automation, data science, and data fusion and visualization services. In addition, the company offers requirements analysis; planning, design, implementation, integration, and enhancement; testing, deployment, maintenance, and quality assurance; application migration and modernization; application development; and documentation and configuration management services, as well as intelligent systems engineering services, including platform innovation and modernization, digital and models-based systems engineering, reliability and maintainability, modeling, simulation and analysis, systems lifecycle support, human factors and safety engineering, systems architecture, and engineering and test and evaluation. Further, it provides professional and technical solutions, and mission support services; command-and-control infrastructure, intelligence, and surveillance and reconnaissance platforms and sensors, as well as the communication, dissemination, and analysis of data; and mission solutions, including C5ISR, training, logistics, supply chain management and sustainment, consulting, and mission planning and execution. The company was founded in 1968 and is headquartered in Herndon, Virginia. As of September 14, 2022, ManTech International Corporation was taken private.

Full MANT Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MANT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MANT vs SCHDMANT vs JEPIMANT vs OMANT vs KOMANT vs MAINMANT vs ABBVMANT vs MRKMANT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.